Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus

Authors: Arin, M.J.; Engert, A.; Krieg, T.; Hunzelmann, N.

Source: British Journal of Dermatology, Volume 153, Number 3, September 2005 , pp. 620-625(6)

Buy & download fulltext article:

Price: $48.00 plus tax (Refund Policy)

Abstract:

Summary Background

Pemphigus is a severe autoimmune blistering disorder caused by autoantibodies to desmoglein 1 and 3. The disease course is typically severe, thus requiring multiple immunosuppressive agents. The treatment is still challenging and in some patients with recalcitrant disease, therapies fail and therapeutic options are limited. Objectives

To investigate whether depletion of B lymphocytes that are thought to produce disease-causing autoantibodies shows a long-term benefit in pemphigus. Methods

Five patients diagnosed as having pemphigus vulgaris and pemphigus foliaceus were treated with the monoclonal antibody rituximab. Rituximab was administered intravenously at a dosage of 375 mg m^-2 once weekly for 4 weeks. Results

The treatment was well tolerated and all patients showed a good response over a follow-up period of up to 3 years, allowing immunosuppressive treatment to be reduced or terminated. B-cell depletion persisted for 6–12 months, and in one patient for almost 3 years. Conclusions

This study highlights the prolonged effect and disease control after one single course of rituximab and further extends the spectrum of treatments of bullous autoimmune disorders.

Keywords: autoimmune disease; B cell; CD20; pemphigus; rituximab; therapy

Document Type: Research article

DOI: http://dx.doi.org/10.1111/j.1365-2133.2005.06651.x

Affiliations: 1: Internal Medicine I, University of Cologne, 50924 Cologne, Germany

Publication date: 2005-09-01